International Myotonic Dystrophy Awareness Day 2022 to Take Place September 15th
The NMD4C alongside Muscular Dystrophy Canada (MDC) are proud to be members of a global alliance of over 50 myotonic dystrophy-focused organizations who have once again united to celebrate Myotonic Dystrophy Families Day this past July 23rd, and International Myotonic Dystrophy Awareness Day on September 15th, 2022.
Read the full press release from the Myotonic Dystrophy Foundation to learn more about the 2022 awareness day!
In addition to the Alliance’s core mission of raising myotonic dystrophy awareness among the general population, many members of the Global Alliance for Myotonic Dystrophy Awareness are also leading efforts in two specific areas of focus to maximize our impact in 2022:
1. Awareness and education among clinical care teams,
2. Clinical trial readiness for participants.
Read the original press release from the inaugural Awareness Day to learn more about this alliance!
Read next...
New Publication from the NMD4C Clinical Trial Network Strengthens Trial Capacity in Canada
We are pleased to share a new publication from the NMD4C Clinical Trial Network led by Kerri Lynn Schellenberg, Homira Osman, Maria Masnata, Rhiannon Hicks, Corinne Kagan, Ana Stosic, Stacey Lintern, Erin Beattie, Drs. Hanns Lochmüller, Craig Campbell, and Jean K Mah. This work focuses on the implementation of a coordinated Canadian neuromuscular clinical trial network to enhance trial readiness, capacity, and access in rare disease research.
Canadian-Led Phase II Studies Advance Vamorolone Evidence in Duchenne Muscular Dystrophy
NMD4C investigators contributed to two phase II studies evaluating vamorolone in boys with Duchenne muscular dystrophy across early childhood and adolescence, demonstrating safety, favorable pharmacokinetics, and potential efficacy. Led by Dr. Jean Mah and conducted across Canadian clinical trial sites with national and industry collaborators, the findings supported Health Canada approval of vamorolone as the first treatment for DMD in Canada. Leaders from both the clinical and patient advocacy communities, including Defeat Duchenne Canada, highlighted the impact of collaboration among patients, families, clinicians, and researchers in advancing care and improving access to new therapies.
Advancing AFC in Neuromuscular Medicine: Program Launch & September Workshop
The Royal College has approved National Training Standards for the AFC in Neuromuscular Medicine, creating a formal pathway to recognize enhanced competence with the DRCPSC credential. This designation establishes a national training standard, supports portable certification, and strengthens clinical capacity across Canada. PGME offices can now apply to offer accredited AFC programs, with a goal of five programs submitting applications by the end of 2026.